Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)

Harmony Biosciences Holdings has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $192000.0 for Q1 2021.

• Non-Current Deffered Revenue for Q1 2021 came in at $192000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $192000.0 (changed N/A YoY), and the FY2020 annual result was $212000.0, down 26.13% from the prior year.
• Non-Current Deffered Revenue came in at $192000.0 for Q1 2021 at Harmony Biosciences Holdings, down from $212000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $305000.0 in Q3 2020 to a low of $192000.0 in Q1 2021.
• The 3-year median for Non-Current Deffered Revenue is $249500.0 (2019), against an average of $249000.0.
• Peak annual rise in Non-Current Deffered Revenue reached 26.13% in 2020, while the deepest fall reached 26.13% in 2020.
• Harmony Biosciences Holdings' Non-Current Deffered Revenue stood at $287000.0 in 2019, then dropped by 26.13% to $212000.0 in 2020, then retreated by 9.43% to $192000.0 in 2021.
• The last three Non-Current Deffered Revenue figures came in at $192000.0 (Q1 2021), $212000.0 (Q4 2020), and $305000.0 (Q3 2020), per Business Quant data.